<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554930</url>
  </required_header>
  <id_info>
    <org_study_id>200907001-3</org_study_id>
    <nct_id>NCT01554930</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease</brief_title>
  <official_title>A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to evaluate the effectiveness and safety of Xiyanping injection,a
      traditional Chinese medicine (TCM), in the treatment of severe type of hand, foot, and mouth
      disease (HFMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By adopting a multi-center, randomized and controlled clinical trial, this study is aimed to
      evaluate the effectiveness, safety and economic evaluation of a traditional Chinese medicine,
      Xiyanping injection,for treatment of HFMD, and to provide scientific evidence for the
      construction of TCM methods in treating HFMD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complication rate</measure>
    <time_frame>15 days</time_frame>
    <description>Refering to the ratio of patient having complications such as pulmonary edema, myocarditis，damage of central nervous system，shock, respiratory failure, multiple organ failur etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time of body temperature going back to normal</measure>
    <time_frame>15 days</time_frame>
    <description>Refering to the time of the armpit temperature of lower than 37.0 degrees Celsius, lasting for at least 24 hours, after the medicine is taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time of symptom disappearance</measure>
    <time_frame>15 days</time_frame>
    <description>Referring to the length of time when clinical symptoms and signs totally disappear after the medicine is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety outcome</measure>
    <time_frame>15 days</time_frame>
    <description>Calculated by adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Hand, Foot, and Mouth Disease</condition>
  <arm_group>
    <arm_group_label>Western therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xiyanping injection plus western therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)</intervention_name>
    <description>Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.</description>
    <arm_group_label>Western therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiyanping injection plus western therapy</intervention_name>
    <description>Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.</description>
    <arm_group_label>Xiyanping injection plus western therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of severe hand-foot-mouth disease patients according to
             Hand-Foot-Mouth Disease Treatment Guidelines 2010 issued by China's Ministry of
             Health; More than 1/3 patients should be diagnosed by etiological examination.

          -  Less than 24 hours of occurrence of fever and/or occurrence of tetter or herpes.

          -  Age of 1-13 years.

          -  Patients or their guardians agree to participate in this study and signed the informed
             consent form.

        Exclusion Criteria:

          -  Complicated with other diseases such as neurogenic pulmonary edema, cardiopulmonary
             failure.

          -  Complicated with other serious primary diseases in organ such as congenital heart
             disease, chronic hepatitis, nephritis and blood diseases, etc.

          -  With history of allergies on traditional Chinese medicine.

          -  Patients who using glucocorticoids for based diseases.

          -  Patients who having history of hemolysis.

          -  Patients or their guardians suffering from Psychiatric diseases.

          -  Attending other clinical studies on HFMD after diagnosed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Xiu hui, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing You-An Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhang Guo liang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shi Qin sheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Handan Maternal and Child Health Care Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhu Qin xiong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangxi Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yang tong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liuzhou People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liuzhou People's Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Handan Maternal and Child Health Care Hospital</name>
      <address>
        <city>Handan</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Children's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hamaguchi T, Fujisawa H, Sakai K, Okino S, Kurosaki N, Nishimura Y, Shimizu H, Yamada M. Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis. 2008 May;14(5):828-30. doi: 10.3201/eid1405.071121.</citation>
    <PMID>18439374</PMID>
  </reference>
  <reference>
    <citation>Hosoya M, Kawasaki Y, Sato M, Honzumi K, Hayashi A, Hiroshima T, Ishiko H, Kato K, Suzuki H. Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003. J Clin Microbiol. 2007 Jan;45(1):112-20. Epub 2006 Nov 8.</citation>
    <PMID>17093028</PMID>
  </reference>
  <reference>
    <citation>Yoke-Fun C, AbuBakar S. Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC Microbiol. 2006 Aug 30;6:74.</citation>
    <PMID>16939656</PMID>
  </reference>
  <reference>
    <citation>Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, Huang YC, Shih SR, Chiou ST, Chen PY, Chang HJ, Lin TY. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002 Jun;109(6):e88.</citation>
    <PMID>12042582</PMID>
  </reference>
  <reference>
    <citation>Shen WC, Chiu HH, Chow KC, Tsai CH. MR imaging findings of enteroviral encephaloymelitis: an outbreak in Taiwan. AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1889-95.</citation>
    <PMID>10588115</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFMD</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>Xiyanping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Diseases</mesh_term>
    <mesh_term>Hand, Foot and Mouth Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

